What Is Mesotherapy, and How Is It Used for Hair Loss? A Critical Examination

When one hears “mesotherapy,” the image is often of cosmetic clinics injecting vitamins or growth factors under the skin to rejuvenate. In the realm of hair loss, mesotherapy is applied to the scalp—microinjecting diluted mixtures of drugs, nutrients, or growth stimulators into the skin around hair follicles. The premise is that delivering these substances directly into the dermis near follicles will be more effective—and avoid systemic side effects—than topical or oral administration. Yet, as you read, you should keep in mind that scientifically, mesotherapy for hair loss remains controversial and inadequately validated.

To understand this approach, one must grasp some basic skin anatomy, hair physiology, and pharmacologic principles. The skin has three principal layers: the epidermis (outermost), the dermis (middle), and the subcutaneous layer (deepest). The dermis houses blood vessels, nerve endings, and—the important part in hair loss therapy—hair follicles (which themselves extend into deeper layers). Mesotherapy injections target the dermis (or dermal-epidermal junction) so that substances are as close as possible to follicles, ideally penetrating around 1–4 mm deep depending on technique.

Hair follicles undergo cyclical phases: anagen (growth), catagen (transition), and telogen (resting). Many hair loss therapies aim to prolong anagen or reverse miniaturization (shrinking) of follicles. Common approved treatments, such as topical minoxidil and oral finasteride (or its cousins), act systemically or topically. Mesotherapy attempts to deposit agents locally, potentially at lower doses, but with higher localized concentration.

In practice, mesotherapy is conducted via many fine injections across the thinning scalp. Clinicians may use mesoguns (automated injection devices) or manual syringes with thin needles. The injected mixture might include low-dose minoxidil, diluted 5α-reductase inhibitors (like finasteride or dutasteride), vitamins, amino acids, or growth factor preparations. The timing and frequency of sessions vary widely—in studies, from weekly to monthly over multiple months or more. However, the technique details differ significantly among practitioners: some use “nappage” (shallow angled injections), others use “point-by-point” deeper injections, or “mesoperfusion” (slow infusion) methods. Because such variation exists, the literature is heterogeneous, making comparisons difficult.

Complications are described in the literature. Frequently reported adverse effects include injection pain, redness (erythema), edema (swelling), itching (pruritus), headache, or small hematomas. In rare cases, more serious effects like granulomatous inflammation, fat necrosis, or paradoxical hair loss have been documented, including hair loss after mesotherapy with dutasteride (Duque-Estrada et al., 2009; Reguero Del Cura et al., 2022). Outbreaks of skin infection with atypical (non-tuberculous) mycobacteria have followed mesotherapy (Del-Castillo et al., 2009; Quiñones et al., 2010). A systematic review of 423 such patients reported that these infections came from injections contaminated by the environment, often needed several courses of antibiotics over weeks, and often left scars (Singsing et al., 2022). Because many mesotherapy protocols use off-label agents (i.e. substances not approved specifically for this route or indication), regulatory oversight is weak, and long-term safety is uncertain. To assess the validity of mesotherapy, one must weigh the published evidence. Below is a deeper dive into the key studies, what they show, their methodological limits, and what remains unknown.

Research Evidence: What Has Been Studied, What It Found, and Its Flaws

A 2023 systematic review titled “Systematic review of mesotherapy: a novel avenue for the treatment of hair loss” summarized 27 studies of mesotherapy in hair loss treatment (mainly androgenetic alopecia). **The authors found that several studies report statistically significant improvements in hair growth, but noted that there are no standardized regimens, that adverse effects have been reported, and that larger controlled trials are needed. **

That review notes that some studies used mesotherapy to deliver growth factor or autologous (patient-derived) suspensions, but often without clarity on concentrations or compositions, making replication difficult. Some reports combined mesotherapy with other modalities (e.g. botulinum toxin, vitamins) which confounds attributing effect to one agent Another review, “Current application of mesotherapy in pattern hair loss”, retrieved 12 studies including 253 males and 274 females across randomized controlled trials, nonrandomized controlled trials, and observational designs. **It reported that mesotherapy showed “positive efficacy to a certain extent” in all of them and that no significant side effects were reported — but these were small studies, which cannot show that the treatment is safe. **

Yet this same review notes that the sample sizes were too small and that too few studies compared mesotherapy with other treatments, so it cannot show that mesotherapy is as good as, or better than, conventional therapies.

A 2017 systematic review, “Safety and Efficacy of Mesotherapy in the Treatment of Androgenetic Alopecia”, identified five studies totaling 344 patients—three randomized controlled trials (RCTs) and two nonrandomized trials. The authors used multiple literature databases and assessed study quality via the Jadad scale. They concluded that while mesotherapy “leads to improvement” in selected outcomes, the evidence quality is low, and in one study some outcomes did not improve. They cautioned that side effect reporting was limited, and that findings should be considered preliminary.

Because only five studies met their inclusion criteria, and many were small and methodologically weak, the review regarded mesotherapy as “controversial” for androgenetic alopecia.

Mesotherapy with Dutasteride: Clinical and Retrospective Trials

One frequently cited protocol involves injecting dutasteride (a dual 5α-reductase inhibitor) intradermally. A small controlled pilot study (Abdallah et al., 2009, Journal of the Pan Arab League of Dermatologists) gave dutasteride-containing injections to 14 men. A 2020 systematic review (Herz-Ruelas et al., Skin Appendage Disorders) reports a mean gain of about 8 hairs over placebo in that study, and a 2023 letter by Kobiałka and Giordano lists it among studies too small to confirm that the treatment works. The study is not indexed in PubMed, and its full results could not be checked.

A multicentre retrospective study of 541 patients treated in Spanish clinics (Saceda-Corralo et al., J Drugs Dermatol 2022) could assess response to mesotherapy alone in only 86 patients after one year. 33 of those 86 (38.4%) showed marked improvement. Pain at injection was reported by 45.5% of all patients. The study had no control group, so it cannot show that the injections caused the improvement.

A 2024 case series of 10 patients (Nohria et al., JAAD Case Reports) found no statistically significant change in hair density or hair diameter after dutasteride mesotherapy. Results of dutasteride mesotherapy are inconsistent, and large controlled trials are lacking.

Dutasteride safety. Dutasteride is not approved for hair loss in the US, UK or EU, and injecting it into the scalp is off-label. Its US label (Avodart, oral capsules) says it is contraindicated in pregnancy because it may harm a male fetus, and that it is not indicated for use in women. The label also warns that dutasteride can be absorbed through the skin, so women who are or may be pregnant should not handle the capsules. People treated with it should not donate blood until 6 months after the last dose. It lowers PSA (a blood test for prostate cancer) by about 50%, so a doctor needs to know about it before a PSA test. The label says sexual side effects may persist after stopping, and that dutasteride's role in this is unknown. Its post-marketing list also includes depressed mood and male breast cancer, again with the drug's role unknown, and in 2025–2026 the EU and UK regulators added a precautionary warning about mood changes to dutasteride as a possible class effect with finasteride; the UK regulator (MHRA, May 2026) advises anyone taking dutasteride who develops depression or suicidal thoughts to contact a doctor as soon as possible (see the FAQ 'Is finasteride safe?'). These warnings come from the oral product; the injected dose is smaller, but some of the studies above treated women, so the pregnancy warning still applies.

Critiques, Weaknesses, and Knowledge Gaps

Across the literature, recurring critical issues emerge. Many studies mix several active agents (e.g. vitamins, biotin, minoxidil, herbal extracts) in one “cocktail,” so it is impossible to isolate which component, if any, is driving effects. Several trials use subjective or nonstandard outcome measures (patient photos, clinician visual assessment) rather than objective, blinded measurements like trichoscopy or digital hair counts. Long-term safety is underreported: few studies track patients beyond one year, and adverse events may be under-documented. Publication bias is likely: positive results are more likely to appear than negative or null outcomes.

Furthermore, standardization is almost nonexistent: injection depth, spacing, dosage, frequency, and session number vary wildly among studies. This heterogeneity undermines meta-analysis and generalization. The regulatory status is uncertain: none of the mesotherapy “cocktails” are approved by the U.S. Food and Drug Administration specifically for scalp hair loss.

In sum, the body of evidence is suggestive but far from conclusive.

What You Need to Know (From a Critical Perspective)

If mesotherapy were proposed for you or someone you care about, here is a more detached, critical framing of what one must understand (and what remains uncertain):

You need to know that mesotherapy is not an established, consistently validated therapy for hair loss; it is experimental. Any claimed benefits may be modest, inconsistent, or dependent on the specific substances used. You should understand that many studies suffer from methodological flaws, and long-term safety data are lacking. You should grasp the technical terms: what injection depth or pattern means; how dose and concentration matter; the difference between objective vs subjective outcome measures; and the concept of off-label use (using a drug or technique in a way not formally authorized by regulatory authorities).

Before treatment, it is reasonable to ask for measurable, objective assessments (e.g. trichoscopic hair counts, hair density, diameter) before and after treatment—ideally in a blinded way. Ask about how many prior patients were treated, what adverse events occurred, and whether the practitioner has experience using controlled protocols. Cost, repeat treatments and potential complications (infection, inflammation, unintended hair loss) also matter. Ask how the clinic prepares and stores the injected solutions. Informed consent should state that benefit is not guaranteed and that risks exist.

From the research side, you should look for well designed randomized controlled trials (RCTs) with adequate sample sizes, standardized protocols, long follow-up, and careful side effect monitoring. Until those exist, any positive claim must be taken with caution.

So far, research suggests that mesotherapy may produce incremental improvements in hair density or thickness in some individuals, but the evidence is neither robust nor uniform. The injection of dutasteride is among the more studied variants, but even there, results are inconsistent.

In short: mesotherapy is a scientifically intriguing but still speculative option in hair loss therapy—not a replacement for approved treatments.

References

Gupta, A. K., Polla Ravi, S., Wang, T., Talukder, M., Starace, M., & Piraccini, B. M. (2023). Systematic review of mesotherapy: a novel avenue for the treatment of hair loss. Journal of Dermatological Treatment, 34(1). https://pubmed.ncbi.nlm.nih.gov/37558233/

Marzban, S., Amani, B., & Asgharzadeh, A. (2017). Safety and efficacy of mesotherapy in the treatment of androgenetic alopecia: a systematic review. Health Technology Assessment in Action, 1(2). https://htainaction.tums.ac.ir/index.php/hta/article/view/8

Tang, Z., Hu, Y., Wang, J., Fan, Z., Qu, Q., & Miao, Y. (2022). Current application of mesotherapy in pattern hair loss: a systematic review. Journal of Cosmetic Dermatology, 21(10). https://pubmed.ncbi.nlm.nih.gov/35253335/

Saceda-Corralo, D., et al. (2022). Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. Journal of Drugs in Dermatology, 21(7), 742-747. https://pubmed.ncbi.nlm.nih.gov/35816059/

Herz-Ruelas, M. E., Álvarez-Villalobos, N. A., Millán-Alanís, J. M., de León-Gutiérrez, H., Ocampo-Garza, S. S., Gómez-Flores, M., & Grimalt, R. (2020). Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disorders, 6(6), 338-345. https://pubmed.ncbi.nlm.nih.gov/33313048/

Kobiałka, J., & Giordano, U. (2023). Dutasteride mesotherapy in the treatment of androgenetic alopecia (letter). Forum Dermatologicum, 9(3), 129-131. https://journals.viamedica.pl/forum_dermatologicum/article/view/96555

Nohria, A., Desai, D., Páez-García, M. S., Lo Sicco, K. I., & Shapiro, J. (2024). Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: a case series. JAAD Case Reports, 54, 53-58. https://pubmed.ncbi.nlm.nih.gov/39687067/

Aledani, E. M., et al. (2024). Mesotherapy as a promising alternative to minoxidil for androgenetic alopecia: a systematic review. Cureus. https://pmc.ncbi.nlm.nih.gov/articles/PMC11152360/

Duque-Estrada, B., et al. (2009). Alopecia secondary to mesotherapy. Journal of the American Academy of Dermatology, 61(4), 707-709. https://pubmed.ncbi.nlm.nih.gov/19577328/

Reguero Del Cura, L., et al. (2022). Two cases of paradoxical nonscarring alopecia after mesotherapy with dutasteride. Skin Appendage Disorders, 8(1), 46-48. https://pubmed.ncbi.nlm.nih.gov/35118130/

Del-Castillo, M., et al. (2009). Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerging Infectious Diseases, 15(2), 357-359. https://pubmed.ncbi.nlm.nih.gov/19193300/

Quiñones, C., et al. (2010). An outbreak of Mycobacterium fortuitum cutaneous infection associated with mesotherapy. Journal of the European Academy of Dermatology and Venereology, 24(5), 604-606. https://pubmed.ncbi.nlm.nih.gov/19840199/

Singsing, M. E., et al. (2022). Clinical features of mesotherapy-associated non-tuberculous mycobacterial infections: a systematic review. International Journal of Women's Dermatology, 8(4), e059. https://pubmed.ncbi.nlm.nih.gov/39916988/

AVODART (dutasteride) capsules, US prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=960797b3-09b1-4d6a-8ece-8b5d918e93e4

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

European Medicines Agency. (2025, August 22). Finasteride- and dutasteride-containing medicinal products: Article 31 referral outcome (EMA/202053/2025). https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products